MARAVAI LIFESCIENCES HOLDINGS, INC. 8-K

What Happened Maravai LifeSciences Holdings, Inc. (MRVI) filed an 8-K reporting the results of its 2026 Annual Meeting of Shareholders held May 26, 2026. On the March 27, 2026 record date the company had 258,180,170 shares outstanding (147,496,090 Class A; 110,684,080 Class B). A total of 236,082,968 shares were present in person or by proxy, constituting a quorum. Shareholders elected three directors to three-year terms expiring in 2029, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and approved the company's named executive officer compensation on a non-binding advisory basis.

Key Details

• Quorum: 236,082,968 shares present of 258,180,170 outstanding (record date March 27, 2026).
• Director elections (terms to 2029):
  • Bernd Brust — For: 182,998,545; Withheld: 19,825,453; Broker Non-Votes: 33,258,969.51
  • Gregory T. Lucier — For: 179,514,826; Withheld: 23,309,172; Broker Non-Votes: 33,258,969.51
  • Luke Marker — For: 182,239,834; Withheld: 20,584,164; Broker Non-Votes: 33,258,969.51
• Auditor ratification: Deloitte & Touche LLP ratified — For: 234,492,897; Against: 1,246,939; Abstentions: 343,132.
• Advisory vote on executive compensation: Approved (non-binding) — For: 200,054,156.49; Against: 2,457,403; Abstentions: 312,439; Broker Non-Votes: 33,258,969.51.

Why It Matters These voting outcomes confirm the board makeup and maintain continuity in governance and financial oversight (Deloitte as auditor). The advisory approval of executive compensation signals shareholder support for the company's pay practices, though it is non-binding. The presence of substantial broker non-votes reflects shares held in street name where brokers did not vote on certain proposals; investors should note this when assessing shareholder support metrics.